MEDICAL REGULATIONS 6th Edition __________________________________________________________________________________ FEDERATION INTERNATIONALE DE VOLLEYBALL
Avenue de la Gare 12 -CH-1001 Lausanne - SWITZERLAND
Tel : +41 (21) 345 35 35 Fax : +41 (21) 345 3545 E-Mail : [email protected] Website : www.fivb.org
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 Table of Contents GENDER VERIFICATION REGULATIONS . . 2 ANTIDOPING CONTROL REGULATIONS. 3
2.3 Prohibited Classes of Substances and Prohibited Methods. 4
ACCREDITED LABORATORIES AND TESTING PROCEDURES . 8 MEDICAL CONTROLS FOR REFEREES . 9
4.1 Health Certificate for International Referees . 9
4.2 Illnesses incompatible with Refereeing in FIVB Competitions . 9
4.3 Medical Control during Competitions . 9
MEDICAL INSPECTIONS PRIOR TO COMPETITIONS .11 MEDICAL ASSISTANCE DURING COMPETITIONS .12 NUTRITION OF PLAYERS DURING COMPETITIONS.13 DUTIES OF FIVB MEDIC AL DELEGATE DURING THE COMPETITIONS .14
Athletes' Nutrition and Accommodation .14
ANTIDOPING CONTROL REGULATIONS FOR BEACH VOLLEYBALL.15 HEALTH CERTIFICATES .16 PLAYERS’ & OFFICIALS’ AGREEMENTS.17 ACCREDITATION OF TEAM MEDICAL DOCTOR.18 MEDICAL DOCUMENTS CHECKLIST.19 APPENDICES
Prohibited classes of substances and prohibited methods . 20-24
Sampling procedures in Doping controls . 25-31
Procedure for Accreditation of Laboratories . 32-33
FIVB Official Forms (available on the FIVB web site: http://www.fivb.org)
M-6 - Accreditation Form for Doping Control Laboratories
M-7 - Declaration for Medication administered to Athletes
F-1 - Confidential Data concerning Volleyball Officials
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 GENDER VERIFICATION REGULATIONS
1.1. Female players in FIVB world and official competitions (except youth competitions) are
obliged as and when required to present a Gender Certificate (Appendix 7, Medical Certificate) delivered by the FIVB Medical Commission or the IOC as stated in article
1.3.2 of FIVB Sports Regulations. The Gender card to be numbered in a logical sequence
1.2. If a Gender Certificate is not presented, the competitor will be submitted (if necessary)
to a gender verification medical test conducted by the organisers in accordance with the
regulations and under the supervision of the FIVB Medical Delegate (FIVB “General
Regulations for International Competitions” Art. 6.3.1. Gender Verification Control).
1.3. If an athlete has already received a FIVB Gender certificate but not brought it with her
and she appears in the FIVB list of certificates already issued, she must firstly prove her
identity. She must not undergo another test but instead pay a fine of 100 CHF to the
1.4. The cost of gender verification tests during official FIVB competitions is the responsibility
1.5. The result of the test will be communicated only to the President of the Control
Committee of the competition (article 6.3.2. of FIVB “General Regulations for
1.6. In the case of a "satisfactory" result, the FIVB Medical Delegate delivers a testimonial
(Appendix 2 - FIVB Form M-2) to the competitor with the official FIVB green card
1.7. Should the medical test result be "not satisfactory", the President of the Control
Committee calls a meeting with the FIVB Medical Delegate, the doctor responsible for the
test and the doctor or representative of the team concerned. Immediately a second test
must be performed in order to confirm or reject the previous result. The result of the
caryotype test must be ready within 24 hours after taking the sample. If the second test
is also not satisfactory the player must be withdrawn from the competition.
1.8. If the first test is inconclusive, the player shall undergo more refined tests, as fixed by
the FIVB Medical Delegate. The results can only be communicated to the President of
the FIVB Medical Commission or his authorized representative.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 2. - ANTIDOPING CONTROL REGULATIONS GENERALITIES
2.1.1 The research of performance in sports has always led some persons to look for
external or artificial means to improve their performance. Such behaviour is
against the ethics of both sports and medical science, can be harmful to the
health of the athlete and constitutes as well a clear attempt to cheat in a sports
2.1.2 For these reasons, FIVB, along with other sports organisations, has promulgated
certain rules restricting or forbidding the use of certain substances, methods or
procedures in sports competition. To contravene these regulations constitutes a
“DOPING INFRACTION”. Such infractions may be detected by means of certain
2.1.3 Recommending, proposing, authorizing, condoning or facilitating the use of any
prohibited substance or method, or trafficking therein is thus forbidden, and is
2.1.4 For the purpose of this FIVB antidoping regulation, the definitions of the terms
employed herein are those given in the “Olympic Movement Anti-Doping code”.
The Appendix 1 reproduces as well the list given in the above mentioned Olympic
Movement Anti-doping code and are given only as an example. Any modification
brought to this list by the IOC after its publication in this Medical Code shall
immediately become effective for all FIVB purposes.
2.1.5 FIVB is liable for antidoping control when players are under its accountability such
as international competition or preparative period when players are registered as
participating in Volleyball or Beach Volleyball international competitions (O2 form).
2.1.6 During these periods FIVB organizes antidoping controls either directly or through
WADA. FIVB would organize, in collaboration with local organisers antidoping tests
during competition. FIVB would propose to WADA the player’s list registered on O2
forms immediately after receiving these one from each national federation, usually
3 months prior to competition. WADA would organize out of competition tests and
is accountable for sampling on players registered on O2 forms.
2.1.7 Outside these periods each National Olympic Committee and National Federation
are accountable to assure players probity and respect of Ethics in Volleyball.
ANTIDOPING CONTROLS
2.2.1 Antidoping control is obligatory in all world and official competitions governed by
the FIVB General Regulations for International Volleyball Competitions. Such
control can be carried out at any stage and in any matches of those
competitions, as shall be decided by FIVB. The number of controls will be
determined in the Specific Competition Regulations according to the decision
made by the FIVB Board of Administration, upon recommendation of the FIVB
Medical Commission. Such controls can be performed at other times, either at the
request of FIVB, or the controlling body.
2.2.2 In FIVB competitions, the President of the FIVB Medical Commission or his
representative must ensure the observance of the Antidoping Control Regulations.
2.2.3 In competitions organised under the exclusive responsibility of the
Confederations, other than world and official competitions (e.g. continental club
cups, regional championships, etc.), or by National Federations, anti-doping
control is the responsibility of the respective Confederation or National
Federation. FIVB however shall be immediately informed of the results of such
2.2.4 CHOICE OF PLAYERS AND SAMPLING PROCEDURE (see Appendix 2)
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
2.2.4.1 The player(s) to be subjected to anti-doping control are chosen by
drawing of lots. The material requested is as follows: • Two boxes of different colours with two sets of chips, in different
colours, numbered each of them from 1 to 18. The boxes marked
• Registration forms for antidoping control (M-1) two for each selected
2.2.4.2 All the players who have taken part in the match are drawn. 2.2.4.3 The draw takes place immediately after the end of the match in the
presence of the competing teams' representatives, a Control Committee
member and a member of the local medical service.
2.2.4.4 The Control Committee member responsible for the drawing of lots puts
successively into a box the lots bearing the same numbers as marked on
the shirts of each team's players who have actually participated in the
match. In the same order, each team's representative draws the same number of
lots as that of the anti-doping controls imposed on the team.
2.2.4.5 Should any doubt prevail or should a player be presumed doped, the
Control Committee members on duty at a given match, after consultation
with the FIVB Medical Delegate and the head of the local Anti-doping
Control Section, may decide to submit one or more additional players to
PROHIBITED CLASSES OF SUBSTANCES AND PROHIBITED METHODS
2.3.1 Prohibited classes of substances and prohibited methods
Appendix 1provides the FIVB Medical Commission list of prohibited classes of
2.3.2 All substances belonging to the banned classes may not be used for medical
treatment, even if they are not listed as examples. If substances of the banned
classes are detected in the laboratory, the FIVB Medical Commission will take
action. It should be noted that the presence of the drug in the urine (or, for the
restricted substances, their concentration above a minimal level) constitutes a
SANCTIONS
2.4.1.1 If the A sample is found to be positive for prohibited or restricted
substances (see Appendix1), the concerned player and the team will be
warned of the consequences if the B sample is also found to be positive.
2.4.1.2 A player who refuses to submit to antidoping control, or whom the FIVB
Medical Commission finds guilty of an attempted doping, is immediately
disqualified and loses the right to take further part in the competition.
The additional sanctions for this player are set out in Articles 2.4.4.2 and 2.4.4.3 here below.
2.4.1.3 The penalties set out in this Code may be applied concurrently insofar as
they are compatible and may be accompanied with measures prescribing
regular or unannounced tests of the athlete concerned over a specified
2.4.1.4 Intentional doping can be proved by any means whatsoever, including
2.4.1.5 An epitestosterone concentration in the urine greater than 200
nanograms per millilitre will be investigated as per Art. C.1.b) of Appendix
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
2.4.1.6 The success or failure of the use of a Prohibited Substance or Prohibited
Method is not material. It is sufficient that the Prohibited Substance or
Prohibited Method was used or attempted for the offence of doping to be
2.4.1.7 The penalty for a doping infraction detected on the occasion of an out-
of-competition test shall be the same, mutatis mutandis, and shall take
effect from the date the positive result was recorded or the date on
which the final judgement further to an appeal is pronounced, whichever
2.4.2.1 if the Prohibited Substance used is ephedrine, phenylpropanolamine,
pseudoephedrine, caffeine, strychnine or related substances the sanction
is (in addition to such fine as can be fixed by the FIVB Board of
Administration): • maximum 3-month suspension for the first offence
• 2-year suspension for the second offence
2.4.2.2 If the Prohibited Substance used is one other than those referred to in
paragraph 4.2.1 above, the sanction shall be (in addition to such fine as
can be fixed by the FIVB Board of Administration): • 2-year suspension for the first offence
c) manoeuvres or manipulation that may prevent or distort any test
d) refusal to undergo any test contemplated in this Code;
e) doping for which responsibility is imputable to an official or the
f) complicity or other forms of involvement in an act of doping by
members of a medical, pharmaceutical or related profession;
the sanctions are as follows: a) if the Prohibited Substance used is ephedrine, phenylpropanolamine,
pseudoephedrine, caffeine or strychnine and related substances (in
addition to such fine as can be fixed by the FIVB Board of
maximum 3-month suspension for the first offence
2-year suspension for the second offence
b) if the Prohibited Substance used is one other than those referred to
in paragraph 4.2.1 above or if it is a repeat offence (a repeat
offence being constituted by a further case of doping perpetrated
within a period of ten years after the preceding sanction, whatever
form it took and whatever the reason for it, became final):
2.4.3.1 Any case of doping infraction during a competition automatically leads to
invalidation of the result obtained (the team, in which a player is proved
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
positive or who does not submit to the control, loses the match 0-3 (0-
25, 0-25, 0-25)) with all its consequences, including forfeit of any
medals and prizes, irrespective of any other sanction that may be
applied, subject to the provisions of point 4.1.2 of this article.
2.4.3.2 Should a second player of the team proved doped, the Control
Committee or the FIVB Board of Administration can impose other
HEARINGS AND PROCEDURES
2.5.1 Before a final decision is made on a particular case, a fair hearing shall be granted
to the player (and possibly the other persons concerned). Such hearing should
take into consideration the circumstances (extenuation or not) and the known
facts of the case. During the hearing, it is recommended that the head of the
accredited laboratory that reported the result be consulted. In case the result is
received after the competition, the players have the right to ask for a hearing to
be organized or to send a confidential letter to the President of the FIVB Medical
Commission, if they want circumstances and facts to be taken into consideration. 2.5.1.1 Exceptional Circumstances
When a player declared positive in doping believes that exceptional
circumstances exist, an application should be made to the Control
Committee of the competition (or the relevant competent body after the
competition) through the Head of his/her Delegation before the hearing.
2.5.1.2 Exceptional circumstances include:
a) An allegation that a prohibited substance was given to the player by
b) An allegation that a prohibited substance was taken by mistake.
c) The suggestion that a doctor prescribed that medication in
ignorance of the fact that it contained a prohibited substance.
2.5.2 The Control Committee should consider both the application by the player and the
circumstances surrounding the player's ineligibility. Only if it is convinced that a
serious infringement of justice has taken place, shall it reduce the period of
TRAFFICKING
2.6.1 The penalties for trafficking in Prohibited or restricted Substances are as follows:
2.6.1.1 In the event of trafficking in Prohibited Substances the penalty will be
suspension for life from participation in sport organisation, activity or
2.6.1.2 In addition, the offence(s) may be reported to the competent
administrative and judicial authorities by any interested physical or legal
2.6.2 Any attempt to perform trafficking shall be penalised in the same manner as the
OUT-OF-COMPETITION TESTING OR UNEXPECTED TESTING
2.7.1 Unless specifically requested by the responsible authority, out-of-competition
testing is directed solely at prohibited substances in class I.C. (Anabolic Agents),
I.D. (Diuretics), I.E. (Peptide Hormones, Mimetics and Analogues) and II
(Prohibited Methods). FIVB strongly recommends that all its affiliated National Federations, Clubs and
Confederations organise systematic out-of-competition testing on the players
(male and female) placed under their jurisdiction, in particular during the training
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
However, FIVB retains the right to organise in collaboration with WADA such out-
of-competition testing that it deems necessary in view of particular
circumstances. Such control can be carried out at anytime and anywhere, as shall be decided by
FIVB and eventually in collaboration with WADA. The number of controls will be
determined by FIVB and WADA. Theses controls could be carried out during non-
FIVB world competition (as friendly tournament or regional competition) and will
2.7.2 CHOICE OF PLAYERS AND SAMPLING PROCEDURE
All players present may be submitted to controls. The antidoping officer can
decide to organize drawing of lots between all players or to pick out specific
players. In any case the chosen player has right to finish his training session. In
case of a tournament the player can go to testing only after the player’s last
match of the day. Sampling procedure is the same as an “in-competition test” (see Appendix 2
2.8.1 As per the FIVB Statutes and Regulation, all appeals regarding a sanction taken in
application of this Medical Regulation shall be made to the International Court of
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 3 – ACCREDITED LABORATORIES AND TESTING PROCEDURES ACCREDITED LABORATORIES
3.1.1 For purposes of this Code, those laboratories accredited by the IADA are qualified
to undertake the detection of the presence of Prohibited Substances and the use
3.1.2 Whenever such accredited laboratories are not available, the FIVB Medical
Commission must homologate in advance the laboratory intended to perform the
biochemical analysis, as per Appendix 3.
3.1.3 Reports of samples having been found to contain prohibited substances and/or
excessive amounts of endogenous substances, shall be sent simultaneously by
registered mail and under double sealed envelopes to:
a) the responsible authorities of the organisation having initiated the control
b) the FIVB Medical Commission, Lausanne
c) the NF concerned if not the same as the authority under paragraph (a) The report shall contain the following items: a) Responsible authority
RELEVANT AUTHORITY FOR SANCTIONS
3.2.1 The procedures for selection of athletes (other than for out-of-competition
tests), collection of samples and sample analysis are described above and
3.2.2 Laboratory analysis procedures are contained in Appendix 4 to this Code. 3.2.3 The FIVB Board of Administration is the only organ competent to rule on the
effects of a positive result during an FIVB world or official competition and for out
of competition tests organized by itself or by WADA. It shall request the advice of
the FIVB Medical Commission prior to acting on any positive result. In all other competitions organised by or under the authority of a Confederation
or National Federation, the competent organ of such Confederation or NF shall be
solely responsible for the application of this Code in relation to such competitions
as well as in relation to all tests, which have been conducted out-of-competition. In competitions organised under the authority of other sports organisations, the
Executive Committees of such associations shall be the competent bodies to rule
on the effects of a positive result during such competitions. Each body concerned shall advise the FIVB Medical Commission of all positive
results and the dispositions made in respect thereof and provide such data in
respect of all tests, whether positive results or otherwise, as may be requested
3.2.4 Minor irregularities, which cannot reasonably be considered to have affected the
results of otherwise valid tests, shall have no effect on such results. Minor
irregularities do not include the chain of custody of the sample, improper sealing
of the container(s) in which the sample is stored, failure to request the signature
of the athlete or failure to provide the athlete with an opportunity to be present
or be represented at the opening and analysis of the “B” sample.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 4. MEDICAL CONTROLS FOR REFEREES HEALTH CERTIFICATE FOR INTERNATIONAL REFEREES (See M-5 - Appendix 8) 4.1.1 The fully completed Health Certificate for FIVB Referees must be presented to the
FIVB Medical Commission at the end of December each year.
4.1.2 The fully completed Health Certificate for International Referees must be
presented to the respective Continental Medical Commission at the end of
ILLNESSES THAT ARE INCOMPATIBLE WITH REFEREEING IN FIVB COMPETITIONS
Each case will be examined separately. This list is not final and other illnesses may be added. 4.2.1 Respiratory affections
• Acute or chronic infectious pneumopathy
• Arterial hypertension with complications
• Non-corrected myopia or corrected myopia of over 5 dioptres
• Non-corrected amblyopia (troubles of the field of vision)
• Other acute or chronic troubles of the sight acknowledged by the specialist
• Diabetes with degenerative complications
MEDICAL CONTROL DURING COMPETITIONS
a) Medical control of international referees before official games :
The FIVB must assess the state of health of each first and second referee.
• test of alcohol abuse (FIVB Form M-3 - Appendix 9)FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
c) The local head of medical services responsible for the control of drug abuse
or court doctor must ensure all examinations in the presence of a
representative of the FIVB Medical Commission or in the presence of a
representative of the FIVB Refereeing Commission.
d) The Medical Commission of the FIVB must previously ratify the control
e) The type of test used will indicate the consumption of alcohol during the last
twelve hours in certain specified quantities.
a) Forty-five minutes before the start of the game, the designated referees
b) The method consists of breath analysis based on a reaction of oxidation-
c) The highest level of alcohol permitted is 0.3 promille (g) per litre.
d) In the case of a positive reaction, a second test will be conducted after
e) If the second test is positive, the referee must be changed by the FIVB
f) The reserve referee must undergo the same test as the first referee.
g) If the referee whose alcohol test proved positive contests the results, he
h) The FIVB Refereeing Commission decides on sanctions.
In order to avoid false positive results on the breath analysis, it is advisable not
to consume thirty minutes before the test strong-tasting liquids such as fruit
juice for example, eat any fruit, or use toothpaste, spray or mouthwash, etc.
4.3.3 Facilities for the Medical Control for Referees
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 5. MEDICAL INSPECTIONS PRIOR TO COMPETITIONS Checklist:
Check availability of genetic laboratory for women's competitions;
Check availability of doping laboratory: • equipment and personnel
Check availability of suitable rooms for collection of urine samples corresponding to FIVB
Check disposition of equipment for sampling
Check rooms for First Aid, medical equipment and personnel in the competition and
Discuss with the organiser the daily menu for the players, in accordance with FIVB
Designate hospitals for possible hospitalisation, and medical assistance in the hotels
where the participants will be accommodated.
Check structure of medical services, verify nominations of • Medical Director
• Gender control, genetic laboratory, and sampling personnel
- medical doctor - responsible for antidoping control
- 4 persons for escort of selected players
• one medical doctor, one nurse for First Aid
• one nurse for players' hotel N.B. The inspection must be followed up by a complete written report.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 6. MEDICAL ASSISTANCE DURING COMPETITIONS Checklist:
First Aid facilities, medical doctor and nurse for competition hall.
First Aid in the training halls (nurse, medical supplies).
First Aid in the hotels where the players are accommodated.
Ambulance, equipped as fully as possible, in front of competition gymnasiums and training
Determination of hospital for possible hospitalisation.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 7. NUTRITION OF PLAYERS DURING COMPETITIONS
Recommendations: 1.
Satisfactory quality (complete) a) Proteins
The proteins must be 65% of animal origin and 35% vegetable protein and it is
recommended that more than 1.5 g. of proteins per kg body weight per day be served. b) Vegetables, fruits and salads
c) Superior casseroles, well-cooked and agreeably prepared
Correct distribution of food during the day. Four meals per day are recommended,
adjusted to the schedule of the matches. An ample schedule for the dining room should
be arranged to accommodate everyone's needs.
Avoid serving the same dishes frequently; alternate kinds of meat used such as beef,
pork, poultry, fish as well as cheese and milk.
Liquids - water, juice, soft drinks and milk. One ml. of water is recommended daily for
each thousand calories; four to five litres of bottled liquids, such as bottled water and
soft drinks or natural liquids, such as juice and milk. Bottled water may be drunk until the required amount of liquids has been consumed.
Whatever extra liquids are consumed must be the concern of the consumer.
The organizations must present at least six months before a competition a list of the
menus with quantities specified in grams for each type of food in order that the FIVB
The FIVB Medical Commission has the right and the obligation to check nutrition during
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 DUTIES OF FIVB MEDICAL DELEGATE DURING THE COMPETITIONS
The Medical Delegate as a member of the Control Committee is responsible for the smooth
running of the medical controls and medical assistance during the competition. At the same
time he should be an active member of the Appeal and Protocol Subcommittee with all
corresponding responsibility. 8.1 GENDER VERIFICATION
8.1.1 On arrival in the organizing country the Medical Delegate must contact the
genetic laboratory in order to : • confirm the methodology of testing already accepted during the inspection
• assure the testing at the moment of arrival of the teams, delivery of the
results one day before the competition and the possibility to perform the
8.1.2 The Medical Delegate must check the Medical Certificate presented by the
players on their arrival in accordance with the Gender Verification Regulations.
ANTIDOPING CONTROL
8.2.1 Before the competition the Medical Delegate contacts the laboratory and checks
8.2.2 The Medical Delegate participates in the inspection of competition and training
halls and: • verifies the availability of chips for the drawing of lots
• inspects antidoping control section.
8.2.3 During the competition the Medical Delegate supervises the work of antidoping
MEDICAL CONTROL FOR REFEREES
8.3.1 To inspect the room for referees' medical control. 8.3.2 To check the equipment for alcohol test.
MEDICAL ASSISTANCE
The Medical Delegate must inspect the rooms for first aid in the competition and training
ATHLETES' NUTRITION AND ACCOMMODATION
The Medical Delegate must verify that meals are provided in quality and quantity as
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 ANTIDOPING CONTROL REGULATIONS FOR FIVB BEACH VOLLEYBALL COMPETITIONS
The antidoping control during official FIVB Beach Volleyball competitions (Beach Volleyball
World Tour) is performed under the supervision of the FIVB Medical Commission.
Antidoping controls are obligatory on the last day for the teams ranked 1 to 4 after the
last match of the day and two players per team and per match will be selected by
In the preliminary round drawing of lots of one match per day and at the end of the day
one player per team will be selected by draw.
If doubt prevails or if a player is presumed doped, the member of the Control Committee
in charge, after consultation with the Medical Delegate can decide to submit one or
The selection of the player must be done by drawing of lots by the jury or Medic al
Delegate immediately after the chosen match.
Equipment and sampling materials will be the same as those used in Volleyball.
Containers of two different colours of chips numbered 1 and 2.
The list of the banned substances and the sanctions are absolutely the same as for FIVB
The samples must be sent to an IOC or FIVB accredited laboratory.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 10. HEALTH CERTIFICATES
10.1 The Health Certificate (form M-4, see Appendix 11) should be sent by the FIVB
Secretariat to the countries participating in the competitions six months prior to the
10.2 The Form M-4 must include a declaration of not taking the forbidden substances listed in
the FIVB Antidoping Regulations, and a statement regarding the player's state of health.
10.3 The Form M-4 should be signed by a medical doctor specialised in sports medicine and
the President of the National Federation.
10.4 All players participating in FIVB official Volleyball competitions must present to the
respective Control Committee Health Certificates issued not earlier than two months prior
to the competitions. For Beach Volleyball the M-4 is valid for one year.
10.5 The Health Certificates must be presented during the Preliminary Inquiry on the team's
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 11. PLAYERS & OFFICIALS AGREEMENT
11.1 The Players & Officials Agreement (form M-8, see Appendix 12) should be sent by the
FIVB Secretariat to the countries participating in the competitions six months prior to the
11.2 The Form M-8 must include a declaration of recognition of the exclusive competence of
the FIVB, its officials, its organs and any jurisdictional organs recognized by the FIVB,
and that the player/official waives any right to recourse to civil courts against the FIVB,
its officials, its organs and those recognized by the FIVB.
11.3 The Form M-8 must be certified by the head of delegation. 11.4 The Forms M-8 must be presented during the Preliminary Inquiry on the team's arrival
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 12. ACCREDITATION OF TEAM MEDICAL DOCTOR
12.1 The team doctor should be in possession of FIVB accreditation allowing him to take place
on the bench during the match as a fourth person. (See FIVB Form F-1 - Appendix 14)
12.2 The accreditation will be granted by the FIVB on presentation of the following
documents: • medical diploma of university grade
• letter from National Olympic Committee or National Volleyball Federation
12.3 The application must be approved by the President of the FIVB Medical Commission.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 13. MEDICAL DOCUMENTS CHECKLIST
13.1 Forms for Health Certificates (FIVB Form M-4) and Players Agreement (FIVB Form M-8)
to be sent by FIVB Secretariat to the National Federations of participating teams 6
13.2 Metallic seal of FIVB Medical Commission together with the green cards for women's
competitions to be sent by FIVB to the organisers just before the championships.
13.3 The last number used on a Gender Certificate to be sent by the President of the FIVB
Medical Commission to the Medical Delegate nominated for a women's competition.
13.4 The copy of the reports from the medical inspections to be sent by the President of the
FIVB Medical Commission to the Medical Delegate nominated for the respective
competition no later than two months before the beginning of the competition.
13.5 A sufficient amount of alcohol checkers, corresponding to the number of competition
sites, to be sent by the FIVB to the organiser before the beginning of the competitions.
13.6 Each Medical Delegate nominated by the FIVB for official competitions must contact the
FIVB Sports Event Coordinator no later than one month prior to the event to obtain
information about the documents and equipment sent by the FIVB.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 APPENDIX 1 - Prohibited classes of substances and prohibited methods I . P R O H I B I T E D C L A S S E S O F S U B S T A N C E S A. STIMULANTS
Prohibited Substances in class (A) include the following examples: amineptine, amfepramone, amiphenazole, amphetamine, bambuterol, bromantan, caffeine, carphedon, cathine, cocaine, cropropamide, crotethamide, ephedrine, etamivan, etilamphetamine, etilefrine, fencamfamin, fenetylline, fenfluramine, formoterol, heptaminol, mefenorex, mephentermine, mesocarb, methamphetamine, methoxyphenamine, methylenedioxyamphetamine, methylephedrine, methylphenidate, nikethamide, norfenfluramine, parahydroxyamphetamine, pemoline, pentetrazol, phendimetrazine, phentermine, phenylephrine, phenylpropanolamine, pholedrine, pipradrol, prolintane, propylhexedrine, pseudoephedrine, reproterol, salbutamol, salmeterol, selegiline, strychnine, terbutaline, and related substances
For caffeine the definition of a positive is a concentration in urine greater than 12
** For cathine, the definition of a positive is a concentration in urine greater than 5
micrograms per millilitre. For ephedrine and methylephedrine, the definition of a
positive is a concentration in urine greater than 10 micrograms per millilitre. For
phenylpropanolamine and pseudoephedrine, the definition of a positive is a
concentration in urine greater than 25 micrograms per millilitre.
*** Permitted by inhaler only to prevent and/or treat asthma and exercise-induced
asthma. Written notification of asthma and/or exercise-induced asthma by a
respiratory or team physician is necessary to the relevant medical authority.
NOTE: All imidazole preparations are acceptable for topical use. Vasoconstrictors may be
administered with local anaesthetic agents. Topical preparations (e.g. nasal, ophthalmological,
rectal) of adrenaline and phenylephrine are permitted. B. NARCOTICS
Prohibited Substances in class (B) include the following examples: buprenorphine, dextromoramide, diamorphine (heroin), hydrocodone, methadone, morphine, pentazocine, pethidine, and related substances NOTE: codeine, dextromethorphan, dextropropoxyphene, dihydrocodeine, diphenoxylate,
ethylmorphine, pholcodine, propoxyphene and tramadol are permitted.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 C. ANABOLIC AGENTS
Prohibited Substances in class (C) include the following examples: 1. Anabolic androgenic steroids clostebol, fluoxymesterone, metandienone, metenolone, nandrolone, 19-norandrostenediol, 19-norandrostenedione, oxandrolone, stanozolol, oxymetholone, norethandrolone, methandriol, mesterolone, formebolone, danazol, drostanolone, gestrinone, mibolerone, and related substances androstenediol, androstenedione, dehydroepiandrosterone (DHEA), dihydrotestosterone, testosterone*, oxymesterone, methyltestosterone, dehydrochlormethyltestosterone, and related substances
Evidence obtained from metabolic profiles and/or isotopic ratio measurements may be used to
* The presence of a testosterone (T) to epitestosterone (E) ratio greater than six (6)
to one (1) in the urine of a competitor constitutes an offence unless there is evidence
that this ratio is due to a physiological or pathological condition, e.g. low
epitestosterone excretion, androgen producing tumour, enzyme deficiencies.
* In the case of T/E greater than 6, it is mandatory that the relevant medical authority
conducts an investigation before the sample is declared positive. A full report will be
written and will include a review of previous tests, subsequent tests and any results
of endocrine investigations. In the event that previous tests are not available, the
athlete should be tested unannounced at least once per month for three months. The
results of these investigations should be included in the report. Failure to co-operate
in the investigations will result in declaring the sample positive.
2. Beta-2 agonists bambuterol, clenbuterol, fenoterol, formoterol, reproterol, salbutamol*, terbutaline*, salmeterol, trenbolone, boldenone, and related substances
* Authorised by inhalation as described in Article (I.A.).
For salbutamol, the definition of a positive under the anabolic agent category is a
concentration in urine greater than 500 nanograms per millilitre.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 D. DIURETICS
Prohibited substances in class (D) include the following examples:
acetazolamide, bendroflumethiazide, bumetanide, canrenone, chlortalidone, ethacrynic acid, furosemide, hydrochlorothiazide, indapamide, mannitol (by intravenous injection), mersalyl, spironolactone, triamterene, and related substances E. PEPTIDE HORMONES, MIMETICS AND ANALOGUES clomiphene*, cyclofenil*, tamoxifen* Prohibited Substances in class (E) include the following examples and their analogues and 1. Chorionic Gonadotrophin (hCG) prohibited in males only; 2. Pituitary and synthetic gonadotrophins (LH) prohibited in males only; 3. Corticotrophins (ACTH, tetracosactide); 4. Growth hormone (hGH); 5. Insulin-like Growth Factor (IGF-1);
and all the respective releasing factors and their analogues;
6. Erythropoietin (EPO); 7. Insulin; permitted only to treat athletics with certified insulin-dependent diabetes. Written
certification of insulin-dependent diabetes must be obtained from an endocrinologist or
The presence of an abnormal concentration of an endogenous hormone in class (E) or its
diagnostic marker(s) in the urine of a competitor constitutes an offence unless it has proven
to be due to a physiological or pathological condition. I I . P R O H I B I T E D M E T H O D S
The following procedures are prohibited:
2. Administering artificial oxygen carriers or plasma expanders;
3. Pharmacological, chemical and physical manipulation.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 I I I . CLASSES OF PROHIBITED SUBSTANCES IN CERTAIN CIRCUMSTANCES A. ALCOHOL
Where the rules of a responsible authority so provide, tests will be conducted for ethanol. B. CANNABINOIDS
Where the rules of a responsible authority so provide, tests will be conducted for cannabinoids
(e.g. Marijuana, Hashish). At the Olympic Games, tests will be conducted for cannabinoids. A
concentration in urine of 11-nor-delta 9-tetrahydrocannabinol-9-carboxylic acid (carboxy-
THC) greater than 15 nanograms per millilitre constitutes doping. C. LOCAL ANAESTHETICS
Injectable local anaesthetics are permitted under the following conditions:
bupivacaine, lidocaine, mepivacaine, procaine, and related substances can be
used but not cocaine. Vasoconstrictor agents may be used in conjunction with
only local or intra-articular injections may be administered;
Where the rules of a responsible authority so provide, notification of administration may be
necessary. D. GLUCOCORTICOSTEROIDS
The systemic use of glucocorticosteroids is prohibited when administered orally, rectally or by
intravenous or intramuscular injection. E. BETA-BLOCKERS
Prohibited substances in class (E) include the following examples: acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol. and related substances Where the rules of a responsible authority so provide, tests will be conducted for beta- FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 SUMMARY OF URINARY CONCENTRATIONS ABOVE WHICH IOC ACCREDITED LABORATORIES MUST REPORT FINDINGS FOR SPECIFIC SUBSTANCES
> 5 nanograms / millilitre in females
> 500 nanograms / millilitre (out of competition testing)
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 APPENDIX 2 - S A M P L I N G P R O C E D U R E S I N D O P I N G C O N T R O L S 1. GENERALITIES
The head of the local medical service is responsible for antidoping controls at world and
The antidoping control section is part of the local medical service and the FIVB Medical
All medical and technical personnel involved in anti-doping control at the main and
secondary competition venues must be previously approved by the FIVB Medical
A competitor may be subject to doping control on more than one occasion during the
2. SELECTION OF ATHLETES Before the start of the match
The person in charge of the team must proceed to the Jury table before each match
2.1.1 Legitimating papers of the players (accreditations, ID Cards, passports,…) 2.1.2 FIVB Form M-7 (Appendix 10), i.e., the list of the names of the players and any
therapy used during the past three days (if the player has taken no medicine, the
word "none" must be clearly indicated), duly signed and filled in, IN A SEALED
2.1.3 Form M-8 duly signed, when there is no Preliminary inquiry.
During the match:
The Game Jury President shall check and register the players that actually took part in
After the match:
Shall be present (see Art. 2.4.3): • President of the Game Jury
• Authorized representative of the local Medical services
• The authorized representative of both teams 2.3.1 The team representative(s) shall be given the right to verify the numbers of the
players among which the draw will be conducted, to verify that they actually did
2.3.2 The team representative(s) draws by lot one number among his/her team’s players
for the anti-doping control (according to article 2.4.4). The Game Jury President shall register the result of the draw on the form M-1. The
team representative(s) and the Game Jury President then sign the form, to attest
2.3.3 The designated player(s) identification documents (as per 2.1.1 above), the form
M-1, M-8 and the sealed envelope containing Form M-7 are then handed over to
the authorised representative of the medical service who accompanies the drawn
player(s) and eventually their accompanying persons as per art. 2.4.3 to the anti-
Should any doubt prevail or should a player be presumed doped, the Control Committee
members on duty at a given match, after consultation with the FIVB Medical Delegate
and the head of the local Antidoping Control Section, may decide to submit one or more
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
The NF concerned, hereafter referred to as the delegation, shall be responsible for the
transportation of its own competitors from the Doping Control Station to the Hotel after
completion of the doping control procedures.
COMPETITOR NOTIFICATION AND REGISTRATION FOR DOPING CONTROL
Immediately after the competition or after the determination of the final results, the
competitor selected for doping control shall be handed a Doping Control Notification by a
Doping Control Escort appointed by the Organising Committee, hereafter referred to as
the Escort. The Escort shall also give a Doping Control Pass, which provides access to
the Doping Control Station to the competitor. From then on the Escort shall be physically
beside the competitor and keep the competitor under observation at all times and
accompany him or her to the waiting room at the Doping Control Station designated. The
competitor shall report with his/her accreditation card and Doping Control Pass to the
Doping Control Station immediately and no later than one hour after receipt of the
A person (a team coach, a doctor or a team-mate of the competitor’s delegation) may
accompany the competitor to the Doping Control station and may watch all procedures
except urination. He or she shall be given a Doping Control Pass by the Escort in order to
be able to enter the Doping Control Station. This accompanying person shall possess
proper accreditation and shall be a member of the same delegation as the competitor
except, in special circumstances, the athlete may choose a member of another
The Doping Control Notification shall bear the competitor’s name, accreditation and
starting numbers, if available, and the statement that an accompanying person may be
present when the competitor reports for Doping Control. The competitor has to be
warned, by clear written notice in the Notification, of the possible consequences should
he/she fail to report for the doping control within the given time limit.
Upon presentation of the Doping Control Notification the escort shall enter the time of
notification and the competitor shall sign the form. The Doping Control Notification shall
be in duplicate, one copy to be kept by the competitor and the original to be returned to
the Doping Control Station by the Escort.
Upon arrival at the Doping Control station, the competitor and the accompanying person
shall hand the Doping Control Notification to a Doping Control Officer who records the
actual time of arrival on the Doping Control Notification, signs it and verifies the identity
of the competitor by means of the photo, name and accreditation number on the
The Doping Control Officer shall keep the Doping Control Notification returned by the
Escort and return the copy to the competitor.
The actual time of arrival and the identity of the competitor shall then be noted on the
Should the competitor refuse to sign the Doping Control Notification or fail to report to
the Doping Control Station within the time laid down in paragraph 3.1, this fact shall be
noted on the Doping Control Official Record. In this case the Doping Control officer and
the representative of the FIVB Medical Commission shall sign the Doping Control Official
record. In addition, the representative of the IOC Medical Commission shall inform the
FIVB Control Committee President immediately. The Chairman of the FIVB Control
Committee shall then decide on the further steps to be taken.
Should the competitor report to the Doping Control Station later than one hour after the
time of notification, this fact shall be noted on the Doping Control Notification and the
Doping Control Official Record. The sampling procedures shall still be carried out, as
described below. The representative of the FIVB Medical Commission shall inform the
FIVB Control Committee President immediately.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
3.10 The competitor and the accompanying person shall remain in the Doping Control station
waiting room under the supervision of the Doping Control Officer until he or she is called
into a consulting area. The competitor and any personal belongings he/she or the
accompanying person bring with them (clothing, bags, etc.) may be searched for
evidence of manipulation, upon entering and leaving the Doping Control Station.
3.11 No photographs, video or tape recordings may be taken inside the Doping Control Station
3.12 The original of the Doping Control Notification shall be appended to the Doping Control
SAMPLE TAKING PROCEDURE
Only one competitor at a time shall be called into the consulting area.
In addition to the competitor and his/her accompanying person, only the following
persons may be present in the consulting area:
• a representative of the FIVB Medical Commission
• the Doping Control Technical Officer(s)
The Doping Control Station shall contain a supply of:
a) disposable collection vessels (contained in bags)
b) disposable urine control kits (contained in bags)
c) disposable partial sample kits (contained in bags) The specifications of the collection vessel, urine control kit and partial sample kit are to
be determined by the FIVB Medical Commission in co-operation with the Organising
The competitor shall select a collection vessel, visually check that it is empty and clean,
proceed to the toilet and urinate a minimum of 75 ml into the collection vessel under the
observation of the Doping Control Officer who shall be of the same gender as the
Any clothing preventing the direct observation of the urination shall be removed. The
competitor shall return to the consulting area with the collection vessel containing the
If the requested urine volume of 75 ml has been provided, the competitor shall select a
urine control kit, open it and place the contents on the table in front of him/her. He/she
shall check that the bottles are empty and clean.
The competitor shall pour approximately two thirds of the urine from the collection
vessel into bottle A and one-third into bottle B. A few drops of urine shall remain in the
collection vessel. Next, the competitor shall close the two bottles hermetically and
check that no leakage occurs. The Doping Control Officer may, with permission of the
competitor, assist with the procedures outlined in this paragraph. All remaining urine shall be destroyed immediately after bottles A and B have been
The Doping Control Officer shall measure the specific gravity and pH of the urine left in
collection vessel. The urine pH should not be less than 5 and not greater than 7, and the
urine should have a specific gravity of 1.010 or higher. If the sample does not meet
these specifications, the FIVB Medical Commission representative may require further
The competitor shall declare to the Doping Control Officer any medication and nutritional
supplements that he/she may have taken in the preceding three days. The Doping
Control Officer shall record this statement on the Doping Control Official Record.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
4.8. The Doping Control Officer shall check that the code numbers on the bottles and
shipping containers are identical, and record the code number on the Doping Control
Official Record. The competitor shall then check that the code numbers on the bottles
and shipping containers are identical to that recorded on the Doping Control Official
Record. The competitor shall place the bottles A and B into the respective shipping
containers and close them carefully and the Doping Control Officer shall verify that these
The competitor shall certify, by signing the Doping Control Official Record, that the
entire procedure has been performed according to the rules above.
Any irregularities identified by the competitor or the accompanying person shall be
recorded on the Doping Control Official Record. The Doping Control Official Record shall also be signed by the Doping Control Officer, by
the FIVB Medical Commission representative, and, if present, by the accompanying
person. The competitor shall be given a copy of the Doping Control Official Record.
4.10 If the competitor refuses to give a sample of urine, the possible consequences shall be
pointed out to him/her by the FIVB Medical Commission representative. If the competitor
still refuses, this fact shall be noted in the Doping Control Official Record. The Doping
Control Officer, the FIVB Medical Commission representative, if present, shall sign this.
The competitor and the accompanying person may, if they wish, sign the Doping Control
The FIVB Medical Commission representative shall be responsible for communicating the
refusal to the FIVB Control Committee President.
4.11 If the competitor has produced less than the requested urine volume of 75 ml, the
competitor shall select a partial sample kit and shall pour the urine from the collection
vessel into the bottle. Then the competitor shall close the bottle and check that no
The competitor shall check that the code numbers on the bottle and the partial sample
container are the same. Next, the urine volume and code number shall be recorded on
the Doping Control Official Record and the competitor shall confirm this by signing the
Doping Control Official Record. Finally, the competitor shall insert the bottle into the
partial sample container and close it completely. The Doping Control Officer shall verify
that this is hermetically closed. The Doping Control Officer may, with the agreement of
the competitor, assist with the procedures outlined in this paragraph. The competitor shall return to the waiting room with the partial sample container until
he/she is able to deliver urine again. When the competitor is ready to deliver a further
urine sample, he/she shall return to the consulting area with the partial sample
container, which shall be handed to the doping Control Officer who shall check that the
partial sample container is intact and that the code number corresponds to that
entered in the Doping Control Official Record. The competitor shall then select a new collection vessel and enter the toilet where
he/she shall urinate. The competitor shall return to Consulting Area, open the partial
sample container and pour the content into the collection vessel. If the combined urine
volumes are less than 75 ml, he/she shall select a new partial sample container and
proceed according to the procedure outlined in this paragraph. When the combined volumes total at least 75 ml, the urine sample shall be processed in
accordance with the procedure outlined in paragraphs 3.5 to 3.9 above.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
4.12 The original of the Doping Control Official Record and the annexed Doping Control
Notifications shall be placed in an envelope and the copy shall be placed in a separate
envelope. After recording on the outside of the envelopes the code numbers of the
Doping Control Official Records contained therein and the code number of the transport
container seals, the two envelopes shall be closed. The FIVB Medical Commission
representative shall be responsible for bringing the envelopes to the FIVB Control
Committee President. The envelopes containing the original and the copies shall be kept
closed and placed in separate safes unless their opening is authorised by the FIVB
4.13 At the end of each doping control, the shipping containers containing the A and the B
samples shall be placed in the respective A and B transport containers. Also, the
corresponding laboratory copies for urine samples of the Doping Control Official Record
shall be placed in a separate envelope which shall be placed in the transport container
containing the A samples. Each transport container shall then be sealed with a numbered
4.14 If one or more of the competitors cannot pass the doping control test at the venue
station within the time limits that has been decided by the FIVB Medical Commission and
the Organising Committee, the test may be performed at the Athletes residence, if
suitable, at the discretion of the FIVB Medical Commission representative.
The competitor shall be accompanied by a Doping Control Officer, the FIVB Medical
Commission representative, and the accompanying person if he/she wishes. The FIVB
Medical Commission representative and the Doping Control Officer shall ensure that all
the necessary material for doping control is available at the Athlete residence.
Samples, which have been collected, shall be transported to the Doping Control
Laboratory in accordance with the procedure described in paragraphs 5.1 and 5.2 below.
5. TRANSPORT AND RECEIPT OF THE SAMPLES
The Doping Control Transport Form shall be completed and given together with the
sealed transport containers to the Doping Control Courier, hereafter referred to as the
Courier, who is in charge of transportation of samples collected at each venue to the
Doping Control Laboratory. The records on this form shall include the signature and
accreditation number of the Courier, the seal numbers of the transport containers, the
venue from which the transport containers have come and the departure time of the
Courier. The Doping Control Transport Form shall be signed by the FIVB Medical
Commission representative who is on duty and by the Doping Control Officer. The FIVB
Medical Commission representative shall be responsible for bringing the original of the
Doping Control Transport Form to the FIVB Control Committee President. The courier
shall take a copy of the Doping Control Transport Form to be countersigned by the Head
of Laboratory or staff member designated by him.
The courier shall take the sealed transport containers to the doping control laboratory
without undue delay. At the laboratory, the Head of Laboratory or staff member
designated by him, and recorded in the allotted space on the copy of the Doping Control
Transport Form will check the identity of the courier and seals. Upon delivery of the
transport containers, the Head of Laboratory or staff member designated by him shall
record the arrival time of the transport containers, check that the transport containers
and their seals are intact, record these facts on the copy of the Doping Control
Transport Form, and keep the copy of the Doping Control Transport Form.
After unsealing and opening the A transport container at the laboratory, the shipping
containers therein shall be examined and the code numbers recorded.
The transport container containing the B samples shall be kept sealed at the laboratory
under the direct control of the FIVB Medical Commission and be opened only with the
authorisation of the FIVB Control Committee President.
6. SAMPLE ANALYSIS
The analysis of a sample shall be performed as soon as possible after its arrival at the
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
The analysis of a sample shall be carried out in accordance with the methods, which
have been approved by the FIVB Medical Commission.
In addition to the Head of the Laboratory and the laboratory staff, only the following
persons shall be admitted to the laboratory during sample analysis: • authorised members of the FIVB Medical Commission
• persons with special authorisation from the FIVB Medical Commission
The Head of the Laboratory shall on a daily basis inform the Chairman of the FIVB
Medical Commission or his representative of the results of all the samples analysed.
Should the analysis of the A samples indicate a violation of the FIVB doping control
regulations, the President of the FIVB Medical Commission or his/her representative shall
immediately inform in writing the Manager of the Delegation of the competitor, or his
representative and the Control Committee President. The B sample will be analysed, if
such analysis is requested, at the latest two hours after the result of the A sample has
been notified to the Team Manager of the Delegation of the competitor. Such time shall
be recorded in the communication to the Team Manager. If the result of the analysis of Sample A is received after the competition, it has to be
immediately sent under confidential mail (double envelope) to the Chairman of the FIVB
The analysis of “B” samples shall be carried out in the same laboratory and under the
supervision of a representative of the FIVB Medical Commission. The delegation in
question shall be allowed to send a maximum of three representatives to the laboratory.
Should the delegation not be present at the laboratory, at the time indic ated, the
representative of the FIVB Medical Commission may decide to proceed to the “B”
analysis. The Head of the Laboratory shall inform the representative of the FIVB Medical
Commission of the result of this analysis, which shall be regarded as final, and is not
subject to appeal. The Head of the Laboratory shall supply the representative of the FIVB Medical
Commission with appropriate documentation of the results. The representative of the
FIVB Medical Commission informs immediately the Chairman of the FIVB Medical
Commission (or his representative) of the result of the second analysis. The latter
conveys the information to the Control Committee President. If the result of the analysis of Sample “B” is received after the competition, it has to be
immediately sent under confidential mail (double envelope) to the President of the FIVB
Should the result of the “B” sample not confirm the result of the “A” analysis, the case
is, subject to any decisions made in the context of the competition, which may no longer
be reversed, considered as negative. The Chairman of the FIVB Control Committee
President shall immediately inform the Team Manager of the delegation of the competitor.
Should the result of the “B” sample be positive, the FIVB Control Committee President
shall then call a meeting of the FIVB Control Committee, to which the competitor and not
more than three representatives of the delegation concerned shall be invited. Following
this meeting, the FIVB Control Committee applies the appropriate sanctions and shall
make a recommendation for the FIVB Executive Committee.
The FIVB Control Committee President shall then forward this recommendation to the
President of the FIVB for submission to the FIVB Executive Board, which shall be
6.10 The Team Manager of the delegation of the competitor shall be informed before the
Control Committee and/or the FIVB Executive Committee make any sanction public.
7. DELEGATION OF RESPONSIBILITIES FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
The FIVB Medical Commission President may delegate his responsibilities to such person or
persons as he may designate, at his discretion, from time to time.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 APPENDIX 3 -
P R O C E D U R E F O R A C C R E D I T A T I O N O F L A B O R A T O R I E S
Laboratories accredited by IOC or recognised by WADA are automatically recognised and
accredited for FIVB competitions. Such accreditation is evidenced by a certificate to such
effect signed by the duly authorised representative of the WADA. Such certificate shall specify
the name of the laboratory and the period for which the certificate shall be valid. Certificates
may be issued after the effective date, with retroactive effect.
FIVBAccreditation of analytical Laboratories(See FIVB Form M-6 Appendix 5)
Analytical laboratories which request accreditation must fulfil the following requirements and
answer the relative questionnaire (Form M-6) : 1.1 Provide a list of staff and their qualifications. 1.2 Provide a list of Standard Operating Protocols. 1.3 Provide a list of instrumental resourc es and equipment. Laboratories seeking
accreditation should be aware that definite identification of a Prohibited Substance
requires analysis by mass spectrometry except for peptide hormones and glycoproteins.
1.4 Provide a list of substances, which the laboratory is able to detect and identify. The
minimum repertoire will be the list of examples enumerated in this Code under the
different classes of Prohibited Substances (and their metabolites).
1.5 Provide a list of available reference substances (dope agents and metabolites). 1.6 Provide a list of the excretion studies (dose, etc.) that have been performed on human
volunteers. State the minimum concentration, which can be detected (based on an
excretion study with a reasonable number of serial collections). a)
The list of substances indicated by the FIVB Medical Commission must be
identifiable by analysis in the laboratory (dope agents and metabolites). Reference substances must be available.
Minimum concentration, which can be determined (detected) following the
The maximum time required to obtain a result after receipt of the sample for
It is essential to test the standards of the work of Dope Control Laboratories. The following
rules should be applied for analytical procedure and quality tests required for the accreditation
programme. 1.7.1. The equipment for the following tests must be available (see the IOC Laboratory
Analyses Procedures” as a model to follow in Appendix 4): 1.
High Pressure Liquid Chromatography (HPLC)
Mass Spectrometry (MS) in connection with a Gas Chromatograph (GS) and a
1.7.2. For screening, the following procedure must be applied :
For "Volatile Doping Agents" - GC screening with a nitrogen specific detector (N-
FID) and capilliary column cross-linked with a moderate pollarity phase e.g. SE 54.
Alternative suitable GLC systems may be used.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
For "Heavy Volatile Doping Agents" screening after acid hydrolysis and extraction at
pH 9.5, derivatisation, cross-linked capilliary column, detection with a nitrogen
specific detector (N-FID) or by mass fragmentography (mass specific detection).
Screening procedure for anabolic steroids • Free steroids: After extraction at pH 8.0 - 9.0 trimethylsilylation and detection
by mass fragmentography (mass specific detection).
• Conjugated steroids: After enzymatic hydrolysis, extraction, trimethylsilylation
and detection by mass fragmentography (mass specific detection). Alternatively
an extraction of the free and the conjugated fraction e.g. with XAD-2 may be performed, followed by a separation of the two fractions, treated and analysed as described above. NOTE : DEFINITE IDENTIFICATION OF A DOPING SUBSTANCE REQUIRES ANALYSIS BY MASS LETTERS OF SUPPORT
Laboratories seeking accreditation are requested to provide a letter of support from a National
Authority, such as the NOC, sports governing body or other and any other letters of support
that they might wish the FIVB Medical Commission to consider. The final decision regarding the
acceptance of the letters of support will be made by the FIVB Medical Commission, taking into
account such factors as continuity, volume of workload, long term financial support,
administrative commitment of the host institution, and research activities and
accomplishments, such as publication records of senior staff.
ELIGIBILITY
A laboratory will be considered to be eligible for obtaining FIVB accreditation when the FIVB
Medical Commission completes a positive evaluation of letters of support and additional initial
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 APPENDIX 4 -
L A B O R A T O R Y A N A L Y S I S P R O C E D U R E S 1. LABORATORY ANALYSIS PROCEDURES
Laboratory analysis procedures are described below. A more specific description may be found
in the Amplification of ISO Guide 25 for Doping Control according to the IOC, which can be
submitted to Applicants for IOC Eligibility (see 1; Appendix A) upon request to the IOC Medical
Chain of custody:
The laboratory must have written protocols designed to maintain control and
accountability from the receipt of urine specimens until testing is completed,
results are reported, and while specimens are in storage.
Receiving/preparation:
The laboratory shall be secure at all times: no unauthorised personnel shall be
permitted. Upon receipt of specimens, accession personnel shall inspect packages
for evidence of possible tampering and compare information on specimen bottles
with that on chain of custody forms. Any discrepancies shall be properly noted and
described. Any direct evidence of tampering shall be reported immediately to the
sport organisation and shall also be noted on the chain of custody form, which shall
accompany all specimens during laboratory possession. Specimen bottles and original chain of custody forms will normally be retained
within the accession area until all analyses have been completed. Aliquots and intra
laboratory chain of custody forms shall be used by laboratory personnel for
conducting the initial and confirmatory tests.
Essential equipment:
– High Pressure Liquid Chromatography (HPLC)
– Mass spectrometry (MS) in combination with gas chroma tography (GC)
– High Resolution Mass Spectrometry or Tandem MS
– Additional or alternative equipment recommended by IOC Medical Commission
according to new scientific developments. Information regarding those
technologies, if any, may be requested from the IOC Medical Director.
Screening procedures:
The laboratory must have written protocols for their screening procedures. Sensitive and comprehensive screening methods to eliminate “true negative”
specimens from further consideration must be used. The initial screening
procedures shall be an appropriate technique which meets the requirements of the
IOC Medical Commission. The following procedures represent minimum requirements: For volatile doping agents excreted free: GC screening with a nitrogen specific
detector (NPD) and capillary column, cross linked with a moderate polarity phase.
Alternative detection by MS may be used. For non volatile-doping agents excreted as conjugates: GC/MS screening after
hydrolysis and extraction, derivatization, cross-linked capillary column
chromatography and detection by selected ion monitoring (mass specific
detection). High pressure liquid chromatography for quantification of caffeine. For Anabolic steroids:
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
For free steroids: extraction, derivatization and detection by selected ion
monitoring (mass specific detection or nitrogen specific detection.
Complementary appropriate immunoanalytical methods may be used.).
For free plus conjugated steroids: after enzymatic hydrolysis, extraction,
derivatization and detection by selection monitoring (mass specific
detection). Alternatively separate extracts of the free and the conjugated
fraction, may be performed, each one treated and analysed as described
For low concentrations of anabolic agents, analytical methods capable to
reach 2 ng/ml detection limit such as High Resolution Mass Spectrometry and
Tandem (MS/MS) Mass Spectrometry are requested to the laboratories
accredited by the IOC for doping control analyses. Validation data for other
techniques should be presented to the subcommission Doping and
Biochemistry of Sport for their approval
For Acidic substances, e.g., diuretics and probenecid: Extraction at suitable pH and
derivatization, GC/MS with detection by full scan or selected ion mo nitoring (mass
specific detection). Alternatively, extraction and analysis by high pressure liquid
chromatography. For hCG: a validated immunoassay to detect and quantitate hCG. For confirmation,
a second different immunoassay is required. For other peptidic hormones: specific
techniques and methodologies will be needed following the evolution of scientific
knowledge on this field. Refer to the IOC Medical Commission for updated
information. Laboratories wishing to use screening procedures other than those required by the
IOC Medical Commission shall submit their methods for written approval by the IOC
Confirmation:
A second aliquot of the same sample is used for confirmation. Mass spectrometry
(MS) is the only authorised confirmation method except for peptide hormones and
glycoproteins. MS may be applied in conjunction with gas chromatography (GC) or high
performance liquid chromatography (HPLC). To exclude possible interference from
the biological materials the sample preparation, including the derivatization as well
as the polarity of the gas chromatographic column can be modified whenever
possible or necessary to exclude possible interference as compared with those used
Specimen processing:
Laboratories will normally process specimens by grouping them into batches. The
number of specimens in each batch may vary significantly depending on the size of
the laboratory and its workload. When conducting either screening or confirmatory
testing, every batch shall contain an appropriate number of quality control samples.
The report shall contain the specimen number assigned by the submitting authority, and
results of the tests. All specimens negative on the initial test or negative on the
confirmatory test shall be reported as negative. Only specimens confirmed positive shall be reported positive for a specific Substance.
Results may be transmitted by various electronic means (e.g., teleprinters, facsimile, or
computer) in a manner consistent with a particular program. Copies of all analytical
results shall be available from the laboratory when requested by an appropriate
authority. The IOC Medical Commission suggests the following reporting format for
positive analytical results on sample A. 1.2.1. Administration:
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
Date of receipt of samples at the laboratory
Confirmation that the seal of the container was intact
Confirmation that the seal of the bottle (if any) was intact
Testing programme (in or out-of-competition)
a) pH, specific gravity and appearance of the sample, determined by the
laboratory at the time of the first aliquoting.
Generic name of the identified Prohibited Substance(s) (e.g. testosterone,
caffeine, etc.) with indication of the excess above a fixed cut-off, if
The laboratory should also be prepared to supply the following information on
request by the relevant authority in connection with the identification of the
Prohibited Substance(s) recorded in 1.2.2.(b) above. a)
Summary of the analytical procedures performed in the screening and in the
Copies of the analytical data relevant to establishing the presence of
substances. Normally this documentation will include the analytical data of a
urine blank, a positive control and the sample.
1.2.3 Statistics of IOC accredited laboratories:
The laboratory shall provide the IOC Medical Director with a summary of urine
analysis tests without any personal identifying information, but subdivided into
categories as requested by the IOC Medical Commission. The format for the
reporting will be as defined by the IOC Medical Commission.
1.2.4 Archiving of analytical files results:
All records pertaining to a given urine specimen shall be retained by the laboratory
for a minimum of two (2) years after reporting the results on the A sample. In the
case of a positive A sample, this period should be extended to five (5) years.
The sealed B specimens corresponding to an analytically positive A sample shall be
retained and placed in properly secured long-term 4 C or less storage for at least 90
days after reporting the A result. Within this period a governing body may request the
laboratory to retain the specimen for an additional period of time. This ensures that the
urine specimen will be available for a possible retest during any administrative or
disciplinary proceeding. If the laboratory does not receive a request to retain the
specimen during the initial 90 day period, the specimen may be discarded. However,
specific national programs may have longer storage requirements. The sealed B
specimens corresponding to an analytically negative A sample should be retained for 30
days after the reporting of the results.
The laboratory facilities shall use appropriate security measures to ensure limited and/or
The drug-testing laboratory shall perform all work with its own personnel and equipment
and within its premises, unless otherwise authorised by the IOC Medical Commission.
2. ANALYTICAL PROCEDURES: A SUMMARY OF ORGANIZATIONAL MATTERS
Verify code number, seals, forms, total number of samples
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
Note if code numbers are not readable or not in agreement with the forms or
if the bottles or seals are broken or otherwise defective
Verify the pH after opening the bottle: is the pH basic?
Verify the colour and appearance of urine: is the urine diluted?
Abnormal values may change sample preparation procedures. Screening protocols: 2.1.2 If a positive result is found
Perform additional GC, HPLC or GC/MS tests with the residues of the first
Re-extraction of a second aliquot of the A bottle. If appropriate, modify the
extraction procedure, if possible to get a cleaner and a more concentrated
extract. Modify the derivatization, e.g., no derivative, TMS, NTFATMS,
GCMS obtain correct retention time - correct MS
- selected ion monitoring (with adequate criteria for identification) if a full
Compare the analytical data of the positive sample with that of the reference
2.1.3 Verify all the information collected if in agreement with the known facts and
structure of doping agent or metabolite(s).
2.1.4 Before reporting a positive result, verify whether the B sample is securely stored,
the seal intact and the code number correct.
2.2 Guidelines for the analysis of the B sample
2.2.1 Identify the persons wishing to observe the analysis of the B sample athlete,
expert, representative of the federation, etc.
2.2.2 When not in conflict with other regulations, present the analysis report of the A
sample and the analytical data, leading to the conclusion that the reported
Prohibited Substance is present in the urine of the A sample.
2.2.3 Explain the analytical methods used in the analysis of the A sample and explain
which analytical method will be used to analyse the B sample taking into account
the result of the A sample. As the purpose of the B analysis is only to demonstrate
that the Prohibited Substance found in the A sample is also present in the B
sample, the analytical strategy for the B analysis may be simpler than the one used
for the A sample, as far as the presence of the Prohibited Substance or its relevant
metabolite is unambiguously established, at the direction of the Director of the
2.2.4 Present the B sample for inspection. Verify that the bottles are properly closed,
that the seal of the sample is not broken and that the code number corresponds to
the code number in the corresponding form. Invite the witness or witnesses (if
present) to add additional comments if appropriate. Sign a document confirming the
2.2.5 Break the seal, take the necessary aliquots of the B sample in presence of the
witnesses and proceed with the analysis.
2.2.6 Close the bottle of the B sample and keep it in a locked cool place. 2.2.7 Take through the procedure, as a minimum
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001
a reference urine collected after application of the dope agent or spiked with
2.2.8 Give the witnesses the opportunity to follow all steps of the sample preparation,
extraction, concentration, derivatization and instrumental analysis.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 APPENDIX 5 -
R U L E S O F E T H I C S 1. COMPETITION TESTING
The laboratories shall only accept and analyse samples originating from known sources within
the context of doping control programmes conducted in competitions organised by national and
international sports governing bodies. This includes national and international federations,
National Olympic Committees, national associations, universities, and other similar
organisations. This rule applies to Olympic and non-Olympic sports. Laboratories should ascertain that the programme calls for specimens collected according to
IOC (or similar) guidelines. This includes collection, under observation, of A and B samples,
appropriate sealing conditions, athletes’ declaration with appropriate signatures, formal chain
of custody conditions and adequate sanctions.
2. OUT-OF-COMPETITION TESTING
The laboratories shall accept samples taken during training (or out-of-competition) only if the
following conditions are simultaneously met:
a) that the samples have been collected and sealed under the conditions generally
prevailing in competitions themselves as in 1. above;
b) if the collection is a part of a programme of a national or international sport governing
c) if appropriate sanctions will follow a positive case.
Laboratories shall not accept samples from individual athletes on a private basis or from
individuals acting on their behalf. No laboratory staff shall provide counsel, advice or
information to Participants or others regarding avoidance, evasion or suppression of a positive
test. Laboratories shall not accept samples, for the purposes of either screening or identification,
from commercial or other sources when the conditions in the above paragraph are not
simultaneously met. These rules apply to Olympic and non-Olympic sports.
3. CLINICAL DIAGNOSTIC
Occasionally the laboratory is requested to analyse a sample for a banned drug or endogenous
substance allegedly coming from a hospitalised or ill person in order to assist a physician in the
diagnostic process. Under this circumstance, the laboratory director must explain the pre-
testing issue to the requester and agree subsequently to analyse the sample only if a letter
accompanies the sample and explicitly certifies that the sample is for medical diagnostic or
therapeutical purposes. The letter must also explain the medical reason for the test.
4. CONFIDENTIALITY
The heads of laboratories, their delegates and laboratory staff shall not discuss or comment to
5. RESEARCH
Laboratories are entitled to participate in research programmes provided that the laboratory
director is satisfied with the bona fide nature and the programmes have received proper ethical
6. REFERENCE BIOLOGICAL SAMPLES
Whenever collected, samples collection shall adhere to ethical principles established in each
country for obtention of biological samples.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 7. NEW SUBSTANCES
The IOC accredited laboratories for doping control shall inform the IOC Medical Commission
when they detect a new or suspicious doping agent.
8. FAIR PRICING
Costs for analysis shall be set in accordance with the actual cost of the analysis in the
country in which the laboratory is located.
FIVB Medical Regulations - 6th Edition – Rev. 2 Aug 2001 APPENDIX 6 - ANTIDOPING CONTROL STATION Waiting room Sampling room
Facilities for Anti-Doping Control Station Disposition of waiting room and specimen room with a toilet and shower.
Equipment • Refrigerator with soft drinks
Medical control for referees: • Separate room of 20m2
- registration form for referee control M-3
Equine Veterinarians’ Consensus Report 1 Canadian Veterinary Medical Association 2 American Association of Equine Practioners 3 International League for the Protection of Horses 1 Dr. King is District Veterinarian for the Canadian Food Inspection Agency, Fort Erie, Ontario, Canada and the President of the Ontario Equestrian Federation. He is the official representative of the Canadian Veter
GENERAL NUTRITION, WEIGHT LOSS, AND WASTING SYNDROME KEY TO ABBREVIATED TERMS WITHIN GUIDELINES INTRODUCTION RECOMMENDATION: The clinician should ensure that patients with HIV-associated weight loss are receiving effective ARV therapy (see Chapter 4: Guidelines for the Use of Antiretroviral Therapy ) . Significant weight loss negatively impacts a patient’s quality of life and se
MEDICAL REGULATIONS